The oncogenic role of the aberrant NF-κB network in DLBCL and mutations hitting the players of the NF-κB pathway or their upstream partners have been covered in the literature, e.g., [204,207,208]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.